<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601535</url>
  </required_header>
  <id_info>
    <org_study_id>N2009-03</org_study_id>
    <nct_id>NCT01601535</nct_id>
  </id_info>
  <brief_title>Study of MLN8237 in Combination With Irinotecan and Temozolomide</brief_title>
  <official_title>Phase I/II Study of MLN8237 in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Approaches to Neuroblastoma Therapy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New Approaches to Neuroblastoma Therapy Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the first part of this clinical trial (Phase I portion) is to study the side
      effects, drug breakdown (pharmacokinetics), and dosing of the drug MLN8237 when added to
      standard chemotherapy drugs, irinotecan and temozolomide.

      The goal of the second part of this clinical trial (Phase II portion) is to learn how many
      children and young adults show improvements in their neuroblastoma when treated with the
      combination of MLN8237, irinotecan, and temozolomide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Aurora A kinase has been shown to play an important role in neuroblastoma growth.
      Inhibition of Aurora A kinase activity attenuates the growth of neuroblastoma cells. MLN8237
      is a selective small molecule inhibitor of Aurora A kinase that has completed pediatric
      single-agent phase I testing, as well as stage 1 phase 2 testing in patients with
      Neuroblastoma. MLN8237 showed activity against the NCI-sponsored Pediatric Preclinical
      Testing Program neuroblastoma in vivo panel that exceeded the activity level observed with
      chemotherapy agents routinely used in the treatment of neuroblastoma. Additional in vitro and
      in vivo studies have shown that Aurora A kinase inhibitors result in enhanced cytotoxicity
      when used in combination with chemotherapy. Irinotecan and temozolomide is a commonly used
      salvage regimen for patients with relapsed or refractory neuroblastoma. This combination has
      a modest objective response rate (16%) and is well-tolerated, suggesting that it will provide
      a useful platform for the study of novel compounds in combination with chemotherapy.
      Preclinical studies demonstrate marked enhancement of anti-neuroblastoma activity with the
      addition of MLN8237 to irinotecan and temozolomide. This study therefore evaluates the
      tolerability and activity of MLN8237 in combination with irinotecan and temozolomide in
      children with refractory or relapsed neuroblastoma. Patients receive irinotecan (50
      mg/m2/dose IV) and temozolomide (100 mg/m2/dose orally) once daily for 5 days along with
      MLN8237 orally once daily for 7 days. The doses of irinotecan and temozolomide will be fixed
      and the dose of MLN8237 will be dose-escalated. In the phase I portion of the study, the
      primary aims are to determine the recommended phase II doses of this combination, describe
      the toxicity of this combination, and characterize the pharmacokinetic profile of MLN8237 and
      irinotecan when used in combination. In the phase II portion of the study, the primary aim is
      to determine the objective response rate of this combination in patients with relapsed or
      refractory neuroblastoma. With Amendment 5, the tolerability and pharmacokinetics of an
      MLN8237 oral solution will be evaluated. Optional correlative studies will evaluate UGT1A1
      polymorphisms as predictors of toxicity and archival tumor tissue Aurora A expression as a
      predictor of response with this combination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 25, 2018</completion_date>
  <primary_completion_date type="Actual">July 25, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma</measure>
    <time_frame>21 days, from study day 1</time_frame>
    <description>The MTD was the highest dose level tested at which fewer than two of six patients had first course DLT. Hematologic DLT was defined as grade 4 neutropenia for more than 7 days, need for platelet transfusion for a platelet count of less than 20,000/mL twice within a 7-day period, or greater than 14-day delay in the start of a subsequent course because of neutropenia or thrombocytopenia. Nonhematologic DLT was defined as any nonhematologic toxicity that delayed the start of a subsequent cycle by more than 14 days or any grade ≥3 toxicity with the exception of the following grade 3 toxicities: nausea, vomiting, anorexia, or dehydration resolving to grade ≤ 2 within 72 hours; increase in hepatic transaminase or electrolyte abnormality resolving to grade ≤ 1 within 7 days; diarrhea persisting for less than 72 hours; fever; infection; or febrile neutropenia. DLT definitions included only toxicities deemed at least possibly related to therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) Data Associated With the Determination of the Recommended Phase 2 Dose</measure>
    <time_frame>21 days, from study day 1</time_frame>
    <description>The MTD was the highest dose level tested at which fewer than two of six patients had first course DLT. Hematologic DLT was defined as grade 4 neutropenia for more than 7 days, need for platelet transfusion for a platelet count of less than 20,000/mL twice within a 7-day period, or greater than 14-day delay in the start of a subsequent course because of neutropenia or thrombocytopenia. Nonhematologic DLT was defined as any nonhematologic toxicity that delayed the start of a subsequent cycle by more than 14 days or any grade ≥3 toxicity with the exception of the following grade 3 toxicities: nausea, vomiting, anorexia, or dehydration resolving to grade ≤ 2 within 72 hours; increase in hepatic transaminase or electrolyte abnormality resolving to grade ≤ 1 within 7 days; diarrhea persisting for less than 72 hours; fever; infection; or febrile neutropenia. DLT definitions included only toxicities deemed at least possibly related to therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Alisertib Day 4 Trough, Day 5 Trough and Cmax</measure>
    <time_frame>1st week of cycle 1</time_frame>
    <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Alisertib Tmax and Half-life</measure>
    <time_frame>1st week of cycle 1</time_frame>
    <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Alisertib AUC</measure>
    <time_frame>1st week of cycle 1</time_frame>
    <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Irinotecan Cmax, APC Cmax, SN-38 Cmax, and SN-38G Cmax</measure>
    <time_frame>1st week of cycle 1</time_frame>
    <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Irinotecan AUC, APC AUC, SN-38 AUC, and SN-38G AUC</measure>
    <time_frame>1st week of cycle 1</time_frame>
    <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Irinotecan Clearance</measure>
    <time_frame>1st week of cycle 1</time_frame>
    <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate for Patients With Relapsed or Refractory Neuroblastoma Treated With MLN8237, Irinotecan, and Temozolomide at the Identified MTD</measure>
    <time_frame>Cycles repeated every 21 days for up to 34 cycles.</time_frame>
    <description>Response was graded according to version 1.2 of the NANT response criteria that classifies patients as having one of the following overall response categories based upon underlying response at soft tissue sites, MIBG positive sites, and bone marrow disease: complete response (CR); CR with minimal residual disease (CR-MRD); partial response (PR); minor response (MR); stable disease (SD); and progressive disease (PD). These criteria utilize RECIST criteria for measurable tumors, Curie score for MIBG scan response, and bone marrow (BM) morphology. BM response was graded as CR (required two time points to confirm), CR unconfirmed (one time point only), CR-MRD (bone marrow involvement &lt; 5% at study entry with negative follow-up biopsies), SD, or PD. Patients with at least SD or better underwent central review of MIBG scans, CT scans, and bone marrow pathology slides. Overall responses of CR, CR-MRD, or PR were considered objective responses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aurora A Expression</measure>
    <time_frame>From date of study enrollment to the date of progression or withdrawal from the study, up to 34 cycles (about 2 years).</time_frame>
    <description>To explore whether MYCN status and markers of expression of Aurora A in archival tumor tissue are associated with the antitumor activity of the combination of MLN8237, irinotecan, and temozolomide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UGT1A1 Genotype</measure>
    <time_frame>Day 7 of cycle 1</time_frame>
    <description>To explore whether UGT1A1 genotype is associated with toxicity in children with refractory neuroblastoma treated with the combination of MLN8237, irinotecan, and temozolomide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AURKA Genotype</measure>
    <time_frame>Day 7 of cycle 1</time_frame>
    <description>To explore whether AURKA genotype is associated with antitumor activity in children with refractory neuroblastoma treated with the combination of MLN8237, irinotecan, and temozolomide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One Year Progression Free Survival Rate</measure>
    <time_frame>1 Years after completion of study</time_frame>
    <description>To determine the progression free survival rates for patients with relapsed or refractory neuroblastoma treated with MLN8237, irinotecan, and temozolomide at the identified MTD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
Irinotecan will be administered intravenously during each course on study day 1 through day 5.
Temozolomide will be administered orally during each course on study day 1 through day 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN8237</intervention_name>
    <description>Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan will be administered intravenously during each course on study day 1 through day 5.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide will be administered orally during each course on study day 1 through day 5.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria that need to be met to participate in this study:

          -  Patients must be &gt; 12 months and &lt; 30 years of age when registered on study.

          -  Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less than
             a partial response to standard treatment or persistent neuroblastoma that had at least
             a partial response to standard treatment. All patients must have at least ONE site of
             evaluable disease.

             o Patients who have at least a partial response to standard treatment who still have
             neuroblastoma that can be seen on CT/MRI or MIBG scans must have a surgical biopsy
             done of the tumor to confirm that it is neuroblastoma. Patients with relapsed or
             refractory neuroblastoma do not need to have a biopsy done to enter on study.

          -  Patients must have adequate heart, kidney, liver and bone marrow function. Patients
             who have bone marrow disease must still have adequate bone marrow function to enter
             the study.

          -  MLN8237 must be swallowed as whole tablets. Therefore, patients must be able to
             swallow pills to be eligible for study. One tablet is the size of small breath mint,
             or baby aspirin. Due to the size of MLN8237 tablets, patients must have a body surface
             area of at least 0.38 m2 to be eligible for study. A body surface area is a
             combination of a patient's height and weight. An example of a child with a BSA of 0.45
             is a child that is 25 inches tall and weighs 25 pounds.You can use the link below to
             calculate your child's body surface area and determine if they are too small for this
             trial.

        Patients cannot participate in the study if:

          -  Patients who have received prior MLN8237 are excluded from all phases of the study.
             Patients previously treated with irinotecan and/or temozolomide will be eligible if
             they have not had documented progressive disease during treatment with a regimen
             containing these agents.

          -  They have other medical problems that could get much worse if they had this treatment.

          -  They are on dialysis for bad kidney function.

          -  They are pregnant or breast feeding.

          -  They have active infections such as hepatitis or fungal infections.

          -  They have an allergy to treatment with cefixime and cefpodixime.

          -  They have brain metastasis at study entry, or have received cranial spinal radiation.

          -  They have had an allogeneic stem cell transplant (received stem cell from someone
             else).

          -  They can't cooperate with the special precautions that are needed for this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven DuBois, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comer Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Boston, Dana-Farber Cancer Institute.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <results_first_submitted>May 30, 2019</results_first_submitted>
  <results_first_submitted_qc>July 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2019</results_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT01601535/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DL 1</title>
          <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis optional</description>
        </group>
        <group group_id="P2">
          <title>DL 1B</title>
          <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="P3">
          <title>DL 2B</title>
          <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="P4">
          <title>DL 3B</title>
          <description>alisertib tablets (80 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="P5">
          <title>Ph 2</title>
          <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="P6">
          <title>Oral Solution</title>
          <description>alisertib oral solution (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Started Another Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Started Another Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DL 1</title>
          <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis optional</description>
        </group>
        <group group_id="B2">
          <title>DL 1B</title>
          <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="B3">
          <title>DL 2B</title>
          <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="B4">
          <title>DL 3B</title>
          <description>alisertib tablets (80 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="B5">
          <title>Ph 2</title>
          <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="B6">
          <title>Oral Solution</title>
          <description>alisertib oral solution (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.60" lower_limit="7.39" upper_limit="18.53"/>
                    <measurement group_id="B2" value="6.81" lower_limit="4.70" upper_limit="13.26"/>
                    <measurement group_id="B3" value="7.67" lower_limit="4.34" upper_limit="22.74"/>
                    <measurement group_id="B4" value="6.14" lower_limit="4.66" upper_limit="12.66"/>
                    <measurement group_id="B5" value="10.74" lower_limit="4.36" upper_limit="19.42"/>
                    <measurement group_id="B6" value="3.05" lower_limit="1.69" upper_limit="7.20"/>
                    <measurement group_id="B7" value="7.61" lower_limit="1.69" upper_limit="22.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Irinotecan</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Temozolomide</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma</title>
        <description>The MTD was the highest dose level tested at which fewer than two of six patients had first course DLT. Hematologic DLT was defined as grade 4 neutropenia for more than 7 days, need for platelet transfusion for a platelet count of less than 20,000/mL twice within a 7-day period, or greater than 14-day delay in the start of a subsequent course because of neutropenia or thrombocytopenia. Nonhematologic DLT was defined as any nonhematologic toxicity that delayed the start of a subsequent cycle by more than 14 days or any grade ≥3 toxicity with the exception of the following grade 3 toxicities: nausea, vomiting, anorexia, or dehydration resolving to grade ≤ 2 within 72 hours; increase in hepatic transaminase or electrolyte abnormality resolving to grade ≤ 1 within 7 days; diarrhea persisting for less than 72 hours; fever; infection; or febrile neutropenia. DLT definitions included only toxicities deemed at least possibly related to therapy.</description>
        <time_frame>21 days, from study day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I</title>
            <description>Patients received alisertib tablets at dose levels of 45, 60, and 80 mg/m^2 per day on days 1 to 7 along with irinotecan 50 mg/m^2 intravenously and temozolomide 100 mg/m^2 orally on days 1 to 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma</title>
          <description>The MTD was the highest dose level tested at which fewer than two of six patients had first course DLT. Hematologic DLT was defined as grade 4 neutropenia for more than 7 days, need for platelet transfusion for a platelet count of less than 20,000/mL twice within a 7-day period, or greater than 14-day delay in the start of a subsequent course because of neutropenia or thrombocytopenia. Nonhematologic DLT was defined as any nonhematologic toxicity that delayed the start of a subsequent cycle by more than 14 days or any grade ≥3 toxicity with the exception of the following grade 3 toxicities: nausea, vomiting, anorexia, or dehydration resolving to grade ≤ 2 within 72 hours; increase in hepatic transaminase or electrolyte abnormality resolving to grade ≤ 1 within 7 days; diarrhea persisting for less than 72 hours; fever; infection; or febrile neutropenia. DLT definitions included only toxicities deemed at least possibly related to therapy.</description>
          <units>mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Limiting Toxicity (DLT) Data Associated With the Determination of the Recommended Phase 2 Dose</title>
        <description>The MTD was the highest dose level tested at which fewer than two of six patients had first course DLT. Hematologic DLT was defined as grade 4 neutropenia for more than 7 days, need for platelet transfusion for a platelet count of less than 20,000/mL twice within a 7-day period, or greater than 14-day delay in the start of a subsequent course because of neutropenia or thrombocytopenia. Nonhematologic DLT was defined as any nonhematologic toxicity that delayed the start of a subsequent cycle by more than 14 days or any grade ≥3 toxicity with the exception of the following grade 3 toxicities: nausea, vomiting, anorexia, or dehydration resolving to grade ≤ 2 within 72 hours; increase in hepatic transaminase or electrolyte abnormality resolving to grade ≤ 1 within 7 days; diarrhea persisting for less than 72 hours; fever; infection; or febrile neutropenia. DLT definitions included only toxicities deemed at least possibly related to therapy.</description>
        <time_frame>21 days, from study day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DL 1</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis optional</description>
          </group>
          <group group_id="O2">
            <title>DL 1B</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O3">
            <title>DL 2B</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O4">
            <title>DL 3B</title>
            <description>alisertib tablets (80 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Limiting Toxicity (DLT) Data Associated With the Determination of the Recommended Phase 2 Dose</title>
          <description>The MTD was the highest dose level tested at which fewer than two of six patients had first course DLT. Hematologic DLT was defined as grade 4 neutropenia for more than 7 days, need for platelet transfusion for a platelet count of less than 20,000/mL twice within a 7-day period, or greater than 14-day delay in the start of a subsequent course because of neutropenia or thrombocytopenia. Nonhematologic DLT was defined as any nonhematologic toxicity that delayed the start of a subsequent cycle by more than 14 days or any grade ≥3 toxicity with the exception of the following grade 3 toxicities: nausea, vomiting, anorexia, or dehydration resolving to grade ≤ 2 within 72 hours; increase in hepatic transaminase or electrolyte abnormality resolving to grade ≤ 1 within 7 days; diarrhea persisting for less than 72 hours; fever; infection; or febrile neutropenia. DLT definitions included only toxicities deemed at least possibly related to therapy.</description>
          <units>DLTs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Alisertib Day 4 Trough, Day 5 Trough and Cmax</title>
        <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
        <time_frame>1st week of cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DL 1</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis optional</description>
          </group>
          <group group_id="O2">
            <title>DL 1B</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O3">
            <title>DL 2B</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O4">
            <title>DL 3B</title>
            <description>alisertib tablets (80 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O5">
            <title>Oral Solution</title>
            <description>alisertib oral solution (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Alisertib Day 4 Trough, Day 5 Trough and Cmax</title>
          <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
          <units>µM</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alisertib Day 4 trough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.09" upper_limit="0.98"/>
                    <measurement group_id="O2" value="0.35" lower_limit="0.13" upper_limit="1.38"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.22" upper_limit="4.07"/>
                    <measurement group_id="O4" value="0.73" lower_limit="0.15" upper_limit="1.35"/>
                    <measurement group_id="O5" value="0.47" lower_limit="0.09" upper_limit="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alisertib Day 5 trough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0.12" upper_limit="1.36"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.18" upper_limit="0.65"/>
                    <measurement group_id="O3" value="0.2" lower_limit="0.05" upper_limit="3.31"/>
                    <measurement group_id="O4" value="0.69" lower_limit="0.25" upper_limit="1.27"/>
                    <measurement group_id="O5" value="0.58" lower_limit="0.09" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alisertib Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" lower_limit="1.91" upper_limit="5.92"/>
                    <measurement group_id="O2" value="2.39" lower_limit="1.72" upper_limit="5.92"/>
                    <measurement group_id="O3" value="3.77" lower_limit="2.16" upper_limit="6.76"/>
                    <measurement group_id="O4" value="4.94" lower_limit="3.99" upper_limit="6.22"/>
                    <measurement group_id="O5" value="8.66" lower_limit="3.49" upper_limit="11.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Alisertib Tmax and Half-life</title>
        <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
        <time_frame>1st week of cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DL 1</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis optional</description>
          </group>
          <group group_id="O2">
            <title>DL 1B</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O3">
            <title>DL 2B</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O4">
            <title>DL 3B</title>
            <description>alisertib tablets (80 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O5">
            <title>Oral Solution</title>
            <description>alisertib oral solution (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Alisertib Tmax and Half-life</title>
          <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alisertib Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="1.12" upper_limit="6.93"/>
                    <measurement group_id="O2" value="1.74" lower_limit="0.65" upper_limit="2.9"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0.97" upper_limit="4"/>
                    <measurement group_id="O4" value="2.52" lower_limit="2" upper_limit="3.03"/>
                    <measurement group_id="O5" value="2" lower_limit="0.5" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alisertib Half-life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.20" lower_limit="5.22" upper_limit="9.83"/>
                    <measurement group_id="O2" value="8.61" lower_limit="4.2" upper_limit="18.2"/>
                    <measurement group_id="O3" value="6.19" lower_limit="3.65" upper_limit="20.28"/>
                    <measurement group_id="O4" value="8.54" lower_limit="5.35" upper_limit="10.05"/>
                    <measurement group_id="O5" value="8.34" lower_limit="4.28" upper_limit="16.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Alisertib AUC</title>
        <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
        <time_frame>1st week of cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DL 1</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis optional</description>
          </group>
          <group group_id="O2">
            <title>DL 1B</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O3">
            <title>DL 2B</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O4">
            <title>DL 3B</title>
            <description>alisertib tablets (80 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O5">
            <title>Oral Solution</title>
            <description>alisertib oral solution (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Alisertib AUC</title>
          <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
          <units>µM•hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.15" lower_limit="16.9" upper_limit="65.5"/>
                    <measurement group_id="O2" value="21" lower_limit="15.4" upper_limit="44.9"/>
                    <measurement group_id="O3" value="30.71" lower_limit="19.61" upper_limit="117.03"/>
                    <measurement group_id="O4" value="47.73" lower_limit="32.71" upper_limit="84.67"/>
                    <measurement group_id="O5" value="58.15" lower_limit="32.03" upper_limit="144.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Irinotecan Cmax, APC Cmax, SN-38 Cmax, and SN-38G Cmax</title>
        <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
        <time_frame>1st week of cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DL 1</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis optional</description>
          </group>
          <group group_id="O2">
            <title>DL 1B</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O3">
            <title>DL 2B</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O4">
            <title>DL 3B</title>
            <description>alisertib tablets (80 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O5">
            <title>Ph 2</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O6">
            <title>Oral Solution</title>
            <description>alisertib oral solution (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Irinotecan Cmax, APC Cmax, SN-38 Cmax, and SN-38G Cmax</title>
          <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Irinotecan Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="722" lower_limit="502" upper_limit="880"/>
                    <measurement group_id="O2" value="703" lower_limit="642" upper_limit="5,371"/>
                    <measurement group_id="O3" value="1,238" lower_limit="493" upper_limit="1,757"/>
                    <measurement group_id="O4" value="784" lower_limit="546" upper_limit="987"/>
                    <measurement group_id="O5" value="881" lower_limit="490" upper_limit="1,757"/>
                    <measurement group_id="O6" value="732" lower_limit="422" upper_limit="861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>APC Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" lower_limit="23.1" upper_limit="480.4"/>
                    <measurement group_id="O2" value="59.8" lower_limit="28.2" upper_limit="105"/>
                    <measurement group_id="O3" value="55.8" lower_limit="25.7" upper_limit="76.3"/>
                    <measurement group_id="O4" value="43.4" lower_limit="29.1" upper_limit="49.4"/>
                    <measurement group_id="O5" value="57.1" lower_limit="25.7" upper_limit="132"/>
                    <measurement group_id="O6" value="51.4" lower_limit="15.0" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SN-38 Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="6.6" upper_limit="18.7"/>
                    <measurement group_id="O2" value="12.6" lower_limit="5.8" upper_limit="16.5"/>
                    <measurement group_id="O3" value="12.0" lower_limit="8.8" upper_limit="14.7"/>
                    <measurement group_id="O4" value="11.7" lower_limit="7.0" upper_limit="13.8"/>
                    <measurement group_id="O5" value="10.4" lower_limit="5.19" upper_limit="32.6"/>
                    <measurement group_id="O6" value="8.26" lower_limit="4.62" upper_limit="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SN-38G Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="16.0" upper_limit="46.9"/>
                    <measurement group_id="O2" value="16.9" lower_limit="4.8" upper_limit="23.7"/>
                    <measurement group_id="O3" value="13.8" lower_limit="7.0" upper_limit="26.8"/>
                    <measurement group_id="O4" value="13.0" lower_limit="10.4" upper_limit="24.0"/>
                    <measurement group_id="O5" value="12.8" lower_limit="6.96" upper_limit="50.5"/>
                    <measurement group_id="O6" value="15.2" lower_limit="4.83" upper_limit="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Irinotecan AUC, APC AUC, SN-38 AUC, and SN-38G AUC</title>
        <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
        <time_frame>1st week of cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DL 1</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis optional</description>
          </group>
          <group group_id="O2">
            <title>DL 1B</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O3">
            <title>DL 2B</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O4">
            <title>DL 3B</title>
            <description>alisertib tablets (80 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O5">
            <title>Ph 2</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O6">
            <title>Oral Solution</title>
            <description>alisertib oral solution (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Irinotecan AUC, APC AUC, SN-38 AUC, and SN-38G AUC</title>
          <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
          <units>h·ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Irinotecan AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3,702" lower_limit="2,059" upper_limit="5,772"/>
                    <measurement group_id="O2" value="2,680" lower_limit="1,626" upper_limit="8,492"/>
                    <measurement group_id="O3" value="3,957" lower_limit="3,231" upper_limit="4,301"/>
                    <measurement group_id="O4" value="2,615" lower_limit="2,414" upper_limit="3,288"/>
                    <measurement group_id="O5" value="3,533" lower_limit="1,906" upper_limit="4,301"/>
                    <measurement group_id="O6" value="3,121" lower_limit="2,001" upper_limit="7,970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>APC AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="571" lower_limit="248" upper_limit="3,313"/>
                    <measurement group_id="O2" value="477" lower_limit="197" upper_limit="1,083"/>
                    <measurement group_id="O3" value="511" lower_limit="293" upper_limit="821"/>
                    <measurement group_id="O4" value="418" lower_limit="299" upper_limit="457"/>
                    <measurement group_id="O5" value="511" lower_limit="293" upper_limit="1,429"/>
                    <measurement group_id="O6" value="616" lower_limit="221" upper_limit="985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SN-38 AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" lower_limit="20.5" upper_limit="294.6"/>
                    <measurement group_id="O2" value="52.9" lower_limit="28.4" upper_limit="119.6"/>
                    <measurement group_id="O3" value="80.8" lower_limit="35.0" upper_limit="109.9"/>
                    <measurement group_id="O4" value="72.0" lower_limit="62.6" upper_limit="102.0"/>
                    <measurement group_id="O5" value="90.0" lower_limit="35.0" upper_limit="235"/>
                    <measurement group_id="O6" value="56.7" lower_limit="26.2" upper_limit="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SN-38G AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.5" lower_limit="124.3" upper_limit="325.3"/>
                    <measurement group_id="O2" value="97.6" lower_limit="53.8" upper_limit="243.6"/>
                    <measurement group_id="O3" value="141.8" lower_limit="77.5" upper_limit="298.1"/>
                    <measurement group_id="O4" value="134.4" lower_limit="101.1" upper_limit="237.8"/>
                    <measurement group_id="O5" value="132" lower_limit="71.0" upper_limit="498"/>
                    <measurement group_id="O6" value="136" lower_limit="74.6" upper_limit="673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Irinotecan Clearance</title>
        <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
        <time_frame>1st week of cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DL 1</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis optional</description>
          </group>
          <group group_id="O2">
            <title>DL 1B</title>
            <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O3">
            <title>DL 2B</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O4">
            <title>DL 3B</title>
            <description>alisertib tablets (80 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O5">
            <title>Ph 2</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
          <group group_id="O6">
            <title>Oral Solution</title>
            <description>alisertib oral solution (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma: Irinotecan Clearance</title>
          <description>Outcomes included Alisertib, irinotecan, APC, SN-38, and SN-38G. APC, SN-38, and SN-38G are metabolites of irinotecan.</description>
          <units>L/h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="8.8" upper_limit="29.4"/>
                    <measurement group_id="O2" value="15.7" lower_limit="4.6" upper_limit="27.3"/>
                    <measurement group_id="O3" value="10.4" lower_limit="9.0" upper_limit="31.4"/>
                    <measurement group_id="O4" value="16.0" lower_limit="12.6" upper_limit="20.1"/>
                    <measurement group_id="O5" value="12.6" lower_limit="7.65" upper_limit="31.7"/>
                    <measurement group_id="O6" value="10.3" lower_limit="4.12" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response Rate for Patients With Relapsed or Refractory Neuroblastoma Treated With MLN8237, Irinotecan, and Temozolomide at the Identified MTD</title>
        <description>Response was graded according to version 1.2 of the NANT response criteria that classifies patients as having one of the following overall response categories based upon underlying response at soft tissue sites, MIBG positive sites, and bone marrow disease: complete response (CR); CR with minimal residual disease (CR-MRD); partial response (PR); minor response (MR); stable disease (SD); and progressive disease (PD). These criteria utilize RECIST criteria for measurable tumors, Curie score for MIBG scan response, and bone marrow (BM) morphology. BM response was graded as CR (required two time points to confirm), CR unconfirmed (one time point only), CR-MRD (bone marrow involvement &lt; 5% at study entry with negative follow-up biopsies), SD, or PD. Patients with at least SD or better underwent central review of MIBG scans, CT scans, and bone marrow pathology slides. Overall responses of CR, CR-MRD, or PR were considered objective responses.</description>
        <time_frame>Cycles repeated every 21 days for up to 34 cycles.</time_frame>
        <population>The analysis was performed on 19 phase II patients, with 1 inevaluable patient excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph 2</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate for Patients With Relapsed or Refractory Neuroblastoma Treated With MLN8237, Irinotecan, and Temozolomide at the Identified MTD</title>
          <description>Response was graded according to version 1.2 of the NANT response criteria that classifies patients as having one of the following overall response categories based upon underlying response at soft tissue sites, MIBG positive sites, and bone marrow disease: complete response (CR); CR with minimal residual disease (CR-MRD); partial response (PR); minor response (MR); stable disease (SD); and progressive disease (PD). These criteria utilize RECIST criteria for measurable tumors, Curie score for MIBG scan response, and bone marrow (BM) morphology. BM response was graded as CR (required two time points to confirm), CR unconfirmed (one time point only), CR-MRD (bone marrow involvement &lt; 5% at study entry with negative follow-up biopsies), SD, or PD. Patients with at least SD or better underwent central review of MIBG scans, CT scans, and bone marrow pathology slides. Overall responses of CR, CR-MRD, or PR were considered objective responses.</description>
          <population>The analysis was performed on 19 phase II patients, with 1 inevaluable patient excluded.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR-Minimal Residual Disease (MRD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response Rate (CR + CR-MRD + PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aurora A Expression</title>
        <description>To explore whether MYCN status and markers of expression of Aurora A in archival tumor tissue are associated with the antitumor activity of the combination of MLN8237, irinotecan, and temozolomide</description>
        <time_frame>From date of study enrollment to the date of progression or withdrawal from the study, up to 34 cycles (about 2 years).</time_frame>
        <population>Consisting of patients treated on the Phase 1 (n = 22), Phase 2 (n = 20), and Oral Solution (n = 12) cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Objective Responders</title>
            <description>Consisting of complete response (CR), CR with minimal residual disease (CR-MRD), and partial response (PR).</description>
          </group>
          <group group_id="O2">
            <title>Objective Non-Responders</title>
            <description>Consisting of minor response (MR), stable disease (SD) and progressive disease (PD).</description>
          </group>
        </group_list>
        <measure>
          <title>Aurora A Expression</title>
          <description>To explore whether MYCN status and markers of expression of Aurora A in archival tumor tissue are associated with the antitumor activity of the combination of MLN8237, irinotecan, and temozolomide</description>
          <population>Consisting of patients treated on the Phase 1 (n = 22), Phase 2 (n = 20), and Oral Solution (n = 12) cohorts.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MYCN Amplified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYCN not Amplified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYCN Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYCN Amplified or Myc Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYCN Non-amplified and Myc Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYCN or Myc Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aurora A protein Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aurora A protein Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aurora A protein Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>MYCN Amplified vs. MYCN not Amplified</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Fisher Exact</method>
            <method_desc>MYCN Amplified or Myc Positive vs. MYCN Non-amplified and Myc Negative</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
            <method_desc>Aurora A protein Positive vs. Aurora A protein Negative</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UGT1A1 Genotype</title>
        <description>To explore whether UGT1A1 genotype is associated with toxicity in children with refractory neuroblastoma treated with the combination of MLN8237, irinotecan, and temozolomide</description>
        <time_frame>Day 7 of cycle 1</time_frame>
        <population>Consisting of patients treated on the Phase 1 (n = 22), Phase 2 (n = 20), and Oral Solution (n = 12) cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>First Cycle DLT Yes</title>
            <description>Patients who had DLT in the first cycle of treatment.</description>
          </group>
          <group group_id="O2">
            <title>First Cycle DLT No</title>
            <description>Patients who did not have DLT in the first cycle of treatment.</description>
          </group>
          <group group_id="O3">
            <title>DLT in Any Cycle Yes</title>
            <description>Patients who had DLT in any cycle of treatment.</description>
          </group>
          <group group_id="O4">
            <title>DLT in Any Cycle No</title>
            <description>Patients who did not have DLT in any cycle of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>UGT1A1 Genotype</title>
          <description>To explore whether UGT1A1 genotype is associated with toxicity in children with refractory neuroblastoma treated with the combination of MLN8237, irinotecan, and temozolomide</description>
          <population>Consisting of patients treated on the Phase 1 (n = 22), Phase 2 (n = 20), and Oral Solution (n = 12) cohorts.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UGT1A1 6\6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UGT1A1 6\7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UGT1A1 7\7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UGT1A1 Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.094</p_value>
            <p_value_desc>UGT1A1 6\6 vs. UGT1A1 6\7 vs. UGT1A1 7\7</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <p_value_desc>UGT1A1 6\6 vs. UGT1A1 6\7 vs. UGT1A1 7\7</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AURKA Genotype</title>
        <description>To explore whether AURKA genotype is associated with antitumor activity in children with refractory neuroblastoma treated with the combination of MLN8237, irinotecan, and temozolomide.</description>
        <time_frame>Day 7 of cycle 1</time_frame>
        <population>Consisting of patients treated on the Phase 1 (n = 22), Phase 2 (n = 20), and Oral Solution (n = 12) cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Objective Responders</title>
            <description>Consisting of complete response (CR), CR with minimal residual disease (CR-MRD), and partial response (PR).</description>
          </group>
          <group group_id="O2">
            <title>Objective Non-Responders</title>
            <description>Consisting of minor response (MR), stable disease (SD) and progressive disease (PD).</description>
          </group>
        </group_list>
        <measure>
          <title>AURKA Genotype</title>
          <description>To explore whether AURKA genotype is associated with antitumor activity in children with refractory neuroblastoma treated with the combination of MLN8237, irinotecan, and temozolomide.</description>
          <population>Consisting of patients treated on the Phase 1 (n = 22), Phase 2 (n = 20), and Oral Solution (n = 12) cohorts.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AurkA Codon 31 Summary H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AurkA Codon 31 Summary V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AurkA Codon 31 Summary W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AurkA Codon 31 Summary Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AurkA Codon 57 Summary H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AurkA Codon 57 Summary W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AurkA Codon 57 Summary Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <p_value_desc>AurkA Codon 31 Summary H vs. AurkA Codon 31 Summary V vs. AurkA Codon 31 Summary W</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>AurkA Codon 57 Summary H vs. AurkA Codon 57 Summary W</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One Year Progression Free Survival Rate</title>
        <description>To determine the progression free survival rates for patients with relapsed or refractory neuroblastoma treated with MLN8237, irinotecan, and temozolomide at the identified MTD</description>
        <time_frame>1 Years after completion of study</time_frame>
        <population>The analysis was performed in phase II patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph 2</title>
            <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
          </group>
        </group_list>
        <measure>
          <title>One Year Progression Free Survival Rate</title>
          <description>To determine the progression free survival rates for patients with relapsed or refractory neuroblastoma treated with MLN8237, irinotecan, and temozolomide at the identified MTD</description>
          <population>The analysis was performed in phase II patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From date of study enrollment to the date of progression or withdrawal from the study, up to 34 cycles (about 2 years).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DL 1</title>
          <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis optional</description>
        </group>
        <group group_id="E2">
          <title>DL 1B</title>
          <description>alisertib tablets (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="E3">
          <title>DL 2B</title>
          <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="E4">
          <title>DL 3B</title>
          <description>alisertib tablets (80 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="E5">
          <title>Ph 2</title>
          <description>alisertib tablets (60 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
        <group group_id="E6">
          <title>Oral Solution</title>
          <description>alisertib oral solution (45 mg/m^2/dose x 7 days), irinotecan (50 mg/m^2/dose IV x 5 days), temozolomide (100 mg/m^2/dose orally x 5 days), myeloid growth factor support and cephalosporin diarrhea prophylaxis required</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Movements involuntary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngeal mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="50" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="61" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" events="100" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" events="17" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" events="147" subjects_affected="19" subjects_at_risk="20"/>
                <counts group_id="E6" events="41" subjects_affected="10" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="22" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="9" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="14" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="13" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="17" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="20" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="17" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E6" events="9" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="45" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="27" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" events="50" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" events="14" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" events="88" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E6" events="27" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="18" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="11" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="33" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="37" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" events="52" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="11" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" events="98" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E6" events="17" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral dysesthesia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="29" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="38" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" events="34" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" events="68" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E6" events="24" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Edema trunk</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="24" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="12" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" events="23" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="15" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="8" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="9" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="36" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="32" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="51" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" events="112" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E6" events="23" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="32" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="42" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="23" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="51" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="103" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E6" events="22" subjects_affected="10" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="17" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="27" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="9" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="32" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hemoglobin increased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="32" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="21" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="43" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="14" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" events="111" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E6" events="26" subjects_affected="10" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="43" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="46" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" events="66" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" events="15" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" events="132" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E6" events="41" subjects_affected="12" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="43" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="55" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" events="93" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" events="16" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" events="154" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E6" events="43" subjects_affected="10" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="25" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="22" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="13" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" events="9" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="55" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="57" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" events="89" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" events="15" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" events="150" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E6" events="45" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="40" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="9" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" events="25" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E6" events="17" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="10" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="22" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="27" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E6" events="9" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="17" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="11" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="18" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="18" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="19" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E6" events="14" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="27" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="29" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="22" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E6" events="9" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="13" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="29" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="14" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" events="26" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="10" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E6" events="15" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="25" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" events="18" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="9" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="24" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="23" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penile pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="13" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="14" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="13" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" events="29" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="9" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" events="14" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E6" events="9" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="16" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pharyngeal mucositis</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="22" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="38" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="52" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="86" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E6" events="32" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bullous dermatitis</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="18" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="12" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>As requested, we are reporting all toxicities of all grades, whether or not they are related to the regimen or known to be related to non-treatment causes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>NANT Medical Director</name_or_title>
      <organization>New Approaches to Neuroblastoma Therapy</organization>
      <phone>323-361-5687</phone>
      <email>nantops@chla.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

